市場調查報告書
商品編碼
1298803
2023-2028年按皮膚病、給藥途徑、配銷通路和地區分類的皮膚病藥物市場Dermatological Drugs Market by Dermatological Diseases, Route of Administration, Distribution Channel, and Region 2023-2028 |
2022年,全球皮膚病藥物市場規模達到215.8億美元。展望未來,IMARC Group預計,到2028年,市場規模將達到391.1億美元,在2023-2028年期間,成長率(CAGR)為10.25%。皮膚病發病率的上升,對藥妝需求的增加,以及個人對皮膚健康認知的提高,是推動市場發展的一些關鍵因素。
皮膚病藥物是用於治療各種皮膚病的藥物,包括痤瘡、牛皮癬、濕疹、酒糟鼻、皮膚癌、真菌感染以及其他影響皮膚、頭髮和指甲的疾病。這些藥物可以局部使用、口服或注射,這取決於所治療的皮膚病類型。局部皮膚病藥物,包括藥膏、軟膏、凝膠和噴霧劑,直接應用於皮膚。它們最常用於治療局部皮膚病,如痤瘡或濕疹。另一方面,全身性皮膚病藥物是通過口服或注射,針對皮膚病的根本原因而發揮作用。這些藥物通常用於治療嚴重或廣泛的皮膚病,如銀屑病。這些產品具有美容和製藥的特性,其目的是改善皮膚的整體健康和外觀。此外,皮膚病藥物是由皮膚科醫生或其他具有皮膚健康專業知識的醫療保健專業人員開出的,這使其在全球的需求不斷升級。
該市場主要由牛皮癬、濕疹、痤瘡、酒糟鼻和皮膚癌等皮膚病的日益流行所驅動。此外,老年人口不斷增加,更容易受到這類疾病的影響,是另一個主要的成長誘導因素。除此之外,個人正在廣泛採用藥妝,即具有藥物特性的化妝品,以改善皮膚的整體健康和外觀。再加上個人對保持健康皮膚的重要性的認知不斷提高,對市場成長產生了積極的影響。病人現在更懂得尋求皮膚病的治療,導致皮膚病藥物的整體需求增加。此外,藥物輸送系統的各種技術進步,如經皮貼劑、奈米技術和微針,正在推動皮膚病藥物市場的成長。這些新的給藥系統提高了藥物的療效,增強了病人的依從性。此外,消費者可支配收入的增加,非處方藥的日益普及,以及對現有治療方案認知的提高,是創造全球有利市場前景的其他一些因素。
請注意,這只代表部分公司的名單,完整的名單已在報告中提供。
The global dermatological drugs market size reached US$ 21.58 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 39.11 Billion by 2028, exhibiting a growth rate (CAGR) of 10.25% during 2023-2028. The rising prevalence of skin disorders, the increasing demand for cosmeceuticals, and the growing awareness among individuals about skin health represent some of the key factors driving the market.
Dermatological drugs are medications that are used to treat various skin conditions, including acne, psoriasis, eczema, rosacea, skin cancer, fungal infections, and other disorders affecting the skin, hair, and nails. These drugs can be applied topically, orally, or by injection, depending on the type of skin condition being treated. Topical dermatological drugs, including creams, ointments, gels, and sprays, are directly applied to the skin. They are most commonly used to treat localized skin conditions, such as acne or eczema. On the other hand, systemic dermatological drugs are taken orally or by injection and work by targeting the underlying cause of a skin condition. These drugs are often used to treat severe or widespread skin conditions, such as psoriasis. These products have both cosmetic and pharmaceutical properties, and they are designed to improve the overall health and appearance of the skin. Moreover, dermatological drugs are prescribed by dermatologists or other healthcare professionals with expertise in skin health, which is escalating their demand across the globe.
The market is primarily driven by the increasing prevalence of skin disorders such as psoriasis, eczema, acne, rosacea, and skin cancer. In addition, the rising geriatric population that is more susceptible to such ailments represents another major growth-inducing factor. Besides this, individuals are widely adopting cosmeceuticals, which are cosmetic products with pharmaceutical properties to improve the overall health and appearance of the skin. This, coupled with the growing awareness among individuals about the importance of maintaining healthy skin, is positively influencing the market growth. Patients are now more aware of seeking treatment for skin conditions, leading to an increase in the overall demand for dermatological drugs. Moreover, various technological advancements in drug delivery systems, such as transdermal patches, nanotechnology, and microneedles, are driving the growth of the dermatological drugs market. These new drug delivery systems improve the efficacy of drugs and enhance patient compliance. Furthermore, the rising disposable incomes of consumers, the growing popularity of over the counter (OTC) drugs and the increasing awareness regarding the available treatment options are some of the other factors creating a favorable market outlook across the globe.
IMARC Group provides an analysis of the key trends in each segment of the global dermatological drugs market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on dermatological diseases, route of administration, and distribution channel.
Acne
Dermatitis
Psoriasis
Skin Cancer
Others
The report has provided a detailed breakup and analysis of the dermatological drugs market based on the dermatological diseases. This includes acne, dermatitis, psoriasis, skin cancer, and others. According to the report, psoriasis represented the largest segment.
Oral
Parenteral
Topical
A detailed breakup and analysis of the dermatological drugs market based on the route of administration has also been provided in the report. This includes oral, parenteral, and topical. According to the report, parenteral accounted for the largest market share.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The report has provided a detailed breakup and analysis of the dermatological drugs market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for dermatological drugs. Some of the factors driving the North America dermatological drugs market included the growing prevalence of skin conditions, the rising awareness regarding appearance, and the escalating demand for cosmeceuticals.
The report has also provided a comprehensive analysis of the competitive landscape in the global dermatological drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GSK plc, LEO Pharma A/S (LEO Holding A/S), Novartis AG, Pfizer Inc., Sanofi S.A., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.